Imaging and blood testing to back new ovarian cancer policy
This article was originally published in Clinica
Executive Summary
Serological and radiological testing will be used in England and Wales to monitor the effectiveness of the drug, Caelyx (doxorubicin), in halting the progression of advanced ovarian cancer, if the final appraisal determination issued this week by the UK National Institute for Clinical Excellence (NICE) becomes guidance.